Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Wayfair Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Wayfair Inc trades at $104.22 (market cap $14.79B). The key difference: Wayfair Inc is far larger — about 15.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Wayfair Inc is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Wayfair Inc for 8 Days on average.
| MRVI | W | |
|---|---|---|
Market Cap | $972.90M | $14.79B |
Volume | 4,325,710 | 1,870,669 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $119.05 |
52-Week Low | $2.83 | $57.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $1.08B | $17.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Wayfair (W) trades at $107.99, up 1.74% on the day, with a bullish technical signal from moving averages. The company reported revenue of $12.46B in 2025 but a net loss of $313M, with a negative net income margin of -2.49%. Analyst consensus is positive with a $114.13 price target, and recent news highlights brand expansion and upcoming Q3 2026 earnings.
The outlook for Wayfair hinges on improving profitability amid competitive pressures. While revenue growth is steady, persistent losses and high debt-to-asset ratio of 95.11% pose risks. The stock offers upside to the consensus target but requires monitoring of cost management and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
